Neurophth
Latest round
- Series C
Last raised
- Aug 2023
Total raised
- $240M
Investors
- 21
About Neurophth
Based in Wuhan, China and established in 2016, Neurophth is a biotechnology company that engages in the R&D and production of new drugs for ophthalmic diseases. The company was established by Professor Bin Li, who has over 20 years of clinical practice and academic experience at Tongji Hospital of Tongji Medical College. Moreover, Professor Bin Li characterized the AAV vectors in inherited blindness. The company has three subsidiaries in Shanghai, Suzhou, and US. And it has a production base of 8,000 square meters. In 2020, its product, NFS-01 received the FDA certification and received NMPA clinical IND application for acceptance in January 2021. The company developed more than 10 product pipelines for ophthalmic diseases based on the validated AAV platform. Its product, NFS-01 and NFS-02 are treated for Leber's Hereditary optic neuropathy, which has been into clinical three phases, and clinical two phases, respectively. Its product, NFS-04 is treated for optic neuropathy injury. And its product, NFS-05, is treated for dominantly inherited optic atrophy.
Who invested in Neurophth
21 investors across 5 rounds
See all investors in Neurophth
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Neurophth
Who invested in Neurophth?
Neurophth has 21 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Neurophth raised?
Neurophth has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Neurophth last raise money?
Neurophth's most recent round on record is a Series C, in Aug 2023.
What does Neurophth do?
Based in Wuhan, China and established in 2016, Neurophth is a biotechnology company that engages in the R&D and production of new drugs for ophthalmic diseases.
Where is Neurophth headquartered?
Neurophth is headquartered in Wuhan, China.
Which VCs invest in companies like Neurophth?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Neurophth's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Neurophth? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.